ClinicalTrials.gg
RecruitingNCT04449523SILENT2Updated Nov 14, 2024

Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions

An observational study in Silent Stroke, Silent Cerebral Infarct and Fibrillation, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 8 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
50 Years and older
Sex
All
01

Study summary

Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification.

The investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS.

The primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.

Read the detailed description

Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and searched for in clinical practice. However, although AF is associated with Silent Brain Infarction (SBI), its role in the formation of these lesions is less well established and needs clarification. A multitude of clinical, laboratory, echocardiographic and electrocardiographic parameters are associated with AF. Although no single one of these parameters has sufficient specificity to rule-in AF, their combined use may nevertheless help to identify patients with SBI at highest risk for AF. The study is expected to provide evidence that long term monitoring in subjects with SBI yields similar rates of AF as in AIS patients.

Patients aged ≥65 years with a presumably silent brain lesion in a brain magnetic resonance imaging fulfilling inclusion criteria and consenting get a subcutaneous implantation of a cardiac monitor (Reveal LINQ). Data will be directly transferred to the treating physician by the Medtronic MyCareLink Patient Monitor. In case of a relevant arrhythmia, the respective study site will be informed by the staff of Inselspital. Relevant arrhythmias are defined as follows:

  • First episode of atrial fibrillation (≥30 seconds)
  • Sustained ventricular tachycardia (≥30 seconds)
  • Sustained supraventricular tachycardia (≥30 seconds)
  • Asystoly of ≥6 seconds duration
  • Atrial fibrillation with pause of ≥6 seconds duration
  • Higher degree atrioventricular (AV) block (3° AV bloc; 2:1 AV conduction; 2° AV block type Mobitz)
  • Sustained bradycardia \<30 beats per minute (≥30 seconds) It is the responsibility of the respective study sites to take appropriate actions and inform the patients and treating physicians about relevant findings. The maximal timeframe from data transmission to data analysis is one week and from data transmission to patient notification two weeks.

The expected results of the study would be supportive in introducing long term monitoring to the care pathway in subjects with SBI. Since SBI are more prevalent than AIS and current recommendations very restrictive, this would have a relevant impact on SBI management.

02

Conditions studied

  • Silent Stroke
  • Silent Cerebral Infarct
  • Fibrillation
03

In context

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

This study's planned enrollment of 150 is below the median of 335 across 72 observational studies indexed under Cerebral Infarction.

Browse Cerebral Infarction studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

≥ 50 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age

    • ≥ 65 years
    • ≥ 50 years AND one the following:

      • NT-proBNP >400 pg/mL
      • Left atrial ventricular index >42 ml/m2 or left atrial diameter >46 mm
      • Covert infarctions with cortical involvement in more than one vascular territory (left carotid territory, right carotid territory, vertebrobasilar territory)
  • Written
  • Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:

    • Diffusion weighted imaging (DWI) positive lesions: Focus of restricted diffusion (high DWI signal and low apparent diffusion coefficient value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for multiple sclerosis OR
    • Cavitatory Lesions: ≥ 3 mm in size that follow cerebro-spinal fluid on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR
    • T2 weighted (T2W) hyperintense/T1 weighted (T1W) hypointense lesions:

      • Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR
      • Present within cortical gray matter or deep gray matter nuclei OR
      • A lesion that is new, compared with an MRI performed within 3 months OR
      • T2W hyper/T1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for multiple sclerosis or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning

Exclusion criteria

Exclusion Criteria:

  • History of AF or atrial flutter
  • Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed.
  • Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM))
  • Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM)
  • History of or indication for major cardiac surgery or transcutaneous aortic valve implantation
  • Indication for permanent oral anticoagulation
  • for permanent oral anticoagulation
  • Projected of less than 2 years
  • Active intra- or extracranial high-grade
  • Patient is already included in another clinical trial that will affect the objectives of this study
  • Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
  • Known or suspected non-compliance, drug or alcohol abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cumulative incidence of Arterial Fibrillation (AF) diagnosis over a median of 24 months

    Only adjudicated events will be used for the analysis. An AF episode is defined as lasting more than 30 seconds. A diagnosis of atrial flutter will also be considered as a primary endpoint.

    Time frame: From day 0 to 24 months after inclusion

Secondary outcomes

  1. Time to first diagnosis of AF (lasting ≥30 seconds; ≥6 minutes; ≥1 hour; ≥ 24 hour)

    Time frame: From day 0 to 24 months after inclusion

  2. Burden of AF

    The burden of AF is defined as the amount of time (percentage) in AF during rhythm monitoring. AF burden will be calculated on a monthly basis.

    Time frame: From day 0 to 24 months after inclusion

  3. Time to composite of first diagnosis of AF, stroke and death.

    Time frame: From day 0 to 24 months after inclusion

  4. Incidence of AF diagnosis according to Silent Brain Infarction (SBI) neuroradiological appearance (subcortical small vessel versus embolic pattern involving grey matter) and SBI fulfilling ESUS criteria versus lacunar type.

    Embolic stroke of undetermined source (ESUS)

    Time frame: From day 0 to 24 months after inclusion

  5. Start of oral anticoagulation therapy at 24 months.

    Time frame: At 24 months

  6. Stroke at 24 months

    Time frame: At 24 months

  7. Mortality at 24 months

    Time frame: At 24 months

  8. Prevalence of other possible etiologies for SBI according to a modified TOAST-classification (large artery disease, small artery disease, other specific etiologies, unknown etiology, incomplete workup)

    Time frame: From day 0 to 24 months after inclusion

  9. Incidence of new SBI at 24 months (only if sufficient funding can be obtained for repeat brain MRI at 24 months without contrast agent)

    Time frame: At 24 months

Other outcomes

  1. Time to first diagnosis of AF (lasting ≥30 seconds; ≥6 minutes; ≥1 hour; ≥ 24 hours) until battery depletion of Implantable Cardiac Monitor (ICM) (36-42 month).

    Time frame: From day 0 until battery depletion, expected to be 36 to 42 months

  2. Cumulative incidence of AF diagnosis until battery depletion of ICM

    Time frame: From day 0 to until battery depletion, expected to be 36 to 42 months

07

Study locations

6 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.

Of 32 observational studies under Cerebral Infarction, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 167. This study's planned 87 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2020
First posted
Jun 29, 2020
StartActual
Sep 8, 2020
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04449523
Responsible party
Sponsor
First posted
Jun 29, 2020
Start date
Sep 8, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 14, 2024

Study contacts

Laurent Roten, PD Dr. med.
Contact
laurent.roten@insel.ch
+41 31 632 52 63
Thomas Meinel, Dr. med.
Contact
thomas.meinel@insel.ch
+41 76 49 28 545
Laurent Roten, PD Dr. med.
principal investigator · Inselgruppe AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion